GS 010

Drug Profile

GS 010

Alternative Names: GS010; ND4 gene therapy; rAAV2/2-ND4; RAAV2/2-ND4 vector; Recombinant AAV vector serotype 2 containing the human wild type mitochondrial ND4 gene

Latest Information Update: 22 Feb 2017

Price : $50

At a glance

  • Originator GenSight Biologics
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Leber's hereditary optic atrophy
  • New Molecular Entity No

Highest Development Phases

  • Phase III Leber's hereditary optic atrophy

Most Recent Events

  • 21 Feb 2017 GenSight Biologics completes enrolment in the phase III REVERSE trial for Leber's Hereditary Optic Atrophy in USA, United Kingdom, France, Italy and Germany
  • 20 Dec 2016 Efficacy data from a phase I/II trial in Leber’s Hereditary Optic Neuropathy released by GenSight Biologics
  • 08 Sep 2016 Phase-III clinical trials in Leber's hereditary optic atrophy (In adolescents) in USA, France, United Kingdom (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top